Compare Ginkgo Bioworks Holdings Inc (DNA) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Under Armour Inc Class A — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.11 (market cap $590.53M), while Under Armour Inc Class A trades at $7.09 (market cap $2.79B). The key difference: Under Armour Inc Class A is far larger — about 4.7× Ginkgo Bioworks Holdings Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | UAA | |
|---|---|---|
Market Cap | $590.53M | $2.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $16.14 | $8.14 |
52-Week Low | $5.48 | $4.17 |
Enterprise Value | $627.78M | $4.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Under Armour (UAA) trades at $6.75, down 0.59% on the day, with a mixed technical picture showing bullish moving averages but overbought RSI signals. Fundamentally, the company reported a net loss of $201.27 million in 2025 despite beating EPS expectations in two recent quarters, with revenue declining to $5.16 billion. Analyst sentiment is cautious with a consensus price target of $5.96, below the current price, and news highlights ongoing challenges in North America offset by international growth.
The outlook remains challenging with weak guidance for FY2027 and margin pressure, though international expansion and a recent Dodge collaboration offer potential catalysts. Key risks include persistent North American weakness, rising costs, and high debt levels. Investors face a stock with negative profitability metrics trading above analyst targets, suggesting limited near-term upside absent a significant operational turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
